It is now looking very unlikely that patients with liver cancer will get access to Bayer’s Stivarga on the NHS, after cost regulators issued final draft guidelines rejecting funding for the drug in this setting.
News
UK launch for Bayer’s five-year contraceptive Kyleena
A new long-acting reversible contraception method offering protection from unplanned pregnancy for up to five years has been launched in the UK.
ViiV kicks off PhIII trial of two-drug HIV regimen
ViiV Healthcare, an HIV specialist firm majority owned by GlaxoSmithKline, has announced the launch of a late-stage study investigating the effectiveness of a two-drug regimen programme in patients with HIV.
Biogen reveals Tysabri failure in stroke trial
Biogen has confirmed that it will not pursue further development of Tysabri in acute ischemic stroke (AIS) after a mid-stage study missed primary and secondary efficacy goals.
GSK happy with 3 percent rise in 2017 sales
GlaxoSmithKline has reported a sales hike of 3 percent at constant exchange rates (CER*) for 2017, after growth was recorded across all of its three global businesses.
Scientists discover way to halt breast cancer spread
Scientists have uncovered a key mechanism that facilitates the spread of breast cancer cells, and thus a potential target for new therapeutic approaches in the fight against the disease.
Theravance Ireland signs deal with Janssen Biotech
Theravance Biopharma Ireland has signed a global co-development and commercialisation deal with Janssen Biotech focusing on new treatments for inflammatory intestinal conditions, including ulcerative colitis and Crohn’s disease.
US green light for Gilead’s HIV combo
Gilead’s new combination therapy Biktarvy has been approved by the US Food and Drug Administration for the treatment of HIV.
Trial success for Allergan’s anti-CGRP migraine drug
The first of two pivotal Phase III clinical trials evaluating Allergan’s experimental anti-CGRP migraine drug ubrogepant has met its key goal.
Catapult brokers ‘double-blind’ research alliance with Dundee Uni, ADS
The Medicines Discovery Catapult has brokered a deal between Antimicrobial Discovery Solutions and the University of Dundee to create a neutral space for research into new antimicrobial drugs.
Scotland’s TCB inks CAR-T deal with Japan’s NIPRO
Scotland’s TC Biopharm (TCB) has secured a major investment from Japan with a deal centered on developing a novel gamma-delta CAR-T therapy to treat cancer, as well as a grant from Scottish Enterprise worth £2.7 million to fund preclinical activities.
Ireland procures Sobi therapies for all haemophilia patients
The Republic of Ireland has become the first country in Europe to switch its entire population with haemophilia A and B treated with short-acting replacement clotting factors to Swedish Orphan Biovitrum’s (Sobi) extended half-life therapies Elocta and Alprolix.
NICE restricts NHS use of Roche’s IPF drug Esbriet
Cost regulators for NHS therapies in England and Wales have now issued final guidelines endorsing the use of Roche’s Esbriet to treat patients with idiopathic pulmonary fibrosis (IPF), but only in those with moderate to severe forms of the disease.
Gov’t confirms HPV jabs for men who have sex with men
Men who have sex with men (MSM) will be offered protection against the human papillomavirus (HPV) via a national vaccination programme in England due to be rolled out latest this year, the government has confirmed.
MHRA expands use of Tillotts’ Entocort
The Medicines and Healthcare Products Regulatory Agency (MHRA) has expanded the approved uses of Tillotts Pharma’s Entocort to include the induction of remission in patients with active microscopic colitis (MC).
